Neutralizing antibody directed against the HIV-1 envelope glycoprotein can completely block HIV-1/SIV chimetic virus infections of macaque monkeys

Nature Medicine

Volumn 5, Issue 2, 1999, Pages 204-210

  Shibata, Riri ^a,d   Igarashi, Tatsuhiko ^a   Haigwood, Nancy ^b   Buckler White, Alicia ^c   Ogert, Robert ^a   Ross, William ^a   Willey, Ronald ^a   Cho, Michael W ^a   Martin, Malcolm A ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b SEATTLE BIOMEDICAL RESEARCH INSTITUTE   (United States)

^c GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

^d VaxGen Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NEUTRALIZING ANTIBODY; VIRUS ENVELOPE PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; IMMUNITY; IMMUNIZATION; IMMUNOASSAY; MACACA; NONHUMAN; PRIORITY JOURNAL; PROTEIN PURIFICATION; SIMIAN IMMUNODEFICIENCY VIRUS;

ANIMALS; GENE PRODUCTS, ENV; HIV ANTIBODIES; HIV ENVELOPE PROTEIN GP120; HIV INFECTIONS; HIV-1; HUMANS; IMMUNIZATION, PASSIVE; MACACA; MACACA NEMESTRINA; NEUTRALIZATION TESTS; PAN TROGLODYTES; REASSORTANT VIRUSES; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME; VIRAL LOAD;

ANIMALIA; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; LENTIVIRUS; MACACA; MACACA NEMESTRINA; PAN (APE); PRIMATES; SIMIAE; SIMIAN IMMUNODEFICIENCY VIRUS; SIMIAN-HUMAN IMMUNODEFICIENCY VIRUS; SUS SCROFA;

EID: 0032907674     PISSN: 10788956     EISSN: None     Source Type: Journal    
DOI: 10.1038/5568     Document Type: Article

References (31)

1. Hammon, W.M., Coriell, L.L., Wehrle, P.F. & Stokes Jr., J. Evaluation of Red Cross gamma globulin as a prophylactic agent of poliomyelitis: final report of results based on clinical diagnoses. J. Am. Med. Assoc. 151, 1272-1285 (1953).
2. Janeway, C.A. Use of concentrated human serum α-globulin in the prevention and attenuation of measles. Bull. NY Acad. Med. 21, 202-222 (1945).
3. Groothuis, J.R. et al. Prophylactic administration of respiratory syncytial virus immune globulin to high-risk infants and young children. The Respiratory Syncytial Virus Immune Globulin Study Group. N. Engl. J. Med. 329, 1524-1530 (1993).
4. Beasley, R. P. et al. Efficacy of hepatitis B immune globulin for prevention of perinatal transmission of the hepatitis B virus carrier state: final report of a randomized double-blind, placebo-controlled trial. Hepotology 3, 135-141 (1983).
5. Snydman, D. R. et al. Use of cytomegalovirus immune globulin to prevent cytomegalovirus disease in renal-transplant recipients. N. Engl. J. Med. 317, 1049-1054 (1987).
6. Krugman, S., Ward, R., Giles, J.P. & Jacobs, A.M. Infectious hepatitis: studies on the effect of gamma globulin and on the incidence of inapparent infection. J. Am. Med. Assoc. 174, 83-90 (1960).
7. Virgin IV, H.W., Bassel-Duby, R., Fields, B.N. & Tyler, K.L. Antibody protects against lethal infection with the neurally spreading reovirus type 3 (Dearing). J. Virol. 62, 4594-4604 (1988).
8. Johnson, R.P. Macaque models for AIDS vaccine development. Curr. Opin. Immunol. 8, 554-560 (1996).
9. Bogers, W.M. et al. Protection from HIV-1 envelope-bearing chimeric simian immunodeficiency virus (SHIV) in rhesus macaques infected with attenuated SIV: consequences of challenge. AIDS 9, F13-F18 (1995).
10. Shibata, R. et al. Resistance of previously infected chimpanzees to successive challenges with a heterologous intraclade B strain of human immunodeficiency virus type 1. J. Virol. 70, 4361-4369 (1996).
11. Shibata, R., Siemon, C., Czajak, S.C., Desrosiers, R.C & Martin, M.A. Live, attenuated simian immunodeficiency virus vaccines elicit potent resistance against a challenge with a human immunodeficiency virus type 1 chimeric virus. J. Virol. 71, 8141-8148 (1997).
12. Berman, P. W. et al. Protection of chimpanzees from infection by HIV-1 after vaccination with recombinant glycoprotein gp120 but not gp160. Nature 345, 622-625 (1990).
13. Bruck, C. et al. HIV-1 envelope-elicited neutralizing antibody titres correlate with protection and virus load in chimpanzees. Vaccine 12, 1141-1148 (1994).
14. Emini, E. A. el al. Prevention of HIV-1 infection in chimpanzees by gp120 V3 domain-specific monoclonal antibody. Nature 355, 728-730 (1992).
15. Girard, M. et al. Immunization of chimpanzees confers protection against challenge with human immunodeficiency virus. Proc. Natl. Acad. Sci. USA 88, 542-546 (1991).
16. Prince, A.M. et al Prevention of HIV infection by passive immunization with HIV immunoglobulin. AIDS Res. Hum. Retroviruses 7, 237-239 (1991).
17. Shibata, R. et al. Isolation and characterization of a syncytium-inducing, macrophage/T-cell line-tropic human immunodeficiency virus type 1 isolate that readily infects chimpanzee cells in vitro and in vivo. J. Virol. 69, 4453-4462 (1995).
18. Shibata, R. et al. Reactivation of HIV type 1 in chronically infected chimpanzees following xenostimulation with human cells or with pulses of corticosteroid. AIDS Res. Hum. Retroviruses 13, 377-381 (1997).
19. Arthur, L.O. et al. Challenge of chimpanzees (Pan troglodytes) immunized with human immunodeficiency virus envelope glycoprotein gp120. J. Virol. 63, 5046-5053 (1989).
20. Haigwood N.L. et al. Passive immune globulin therapy in the SIV/macaque model: early intervention can alter disease profile, Immunol. Lett. 51, 107-114 (1996).
21. Shibata, R. et al. Infection and pathogenicity of chimeric simian-human immunodeficiency viruses in macaques: determinants of high virus loads and CD4 cell killing. J. Infect. Dis. 176, 362-373 (1997).
22. Gauduin, M.C. et al. Passive immunization with a human monoclonal antibody protects hu-PBL-SCID mice against challenge by primary isolates of HIV-1. Nature Med. 3, 1389-1393 (1997).
23. Reed, L.J. & Muench, H. A simple method of estimating fifty percent endpoints. Am. J. Hyg. 27, 493-497 (1938).
24. Willey, R.L., Shibata, R., Freed, E.O., Cho, M.W. & Martin, M.A. Differential glycosylation, virion incorporation, and sensitivity to neutralizing antibodies of human immunodeficiency virus type 1 envelope produced from infected primary T-lymphocyte and macrophage cultures. J. Virol. 70, 6431-6436 (1996).
25. Moore, J. & Trkola, A. HIV type 1 coreceptors, neutralization serotypes, and vaccine development. AIDS Res. Hum. Retroviruses 13, 733-736 (1997).
26. Stott, E.J. Towards a vaccine against AIDS: lessons from simian immunodeficiency virus vaccines. Curr. Top. Microbiol. Immunol. 188, 221-237 (1994).
27. Willey, R.L., Martin, M.A. & Peden, K.W.C. Increase in soluble CD4 binding to and CD4-induced dissociation of gp120 from virions correlates with infectivity of human immunodeficiency virus type 1. J. Virol. 68, 1029-1039 (1994).
28. Cho, M.W., Lee, M.K., Carney, M.C., Berson, J.F., Doms, R.W. & Martin, M.A. Identification of determinants on a dualtropic human immunodeficiency virus type 1 envelope glycoprotein that confer usage of CXCR4. J. Virol. 72, 2509-2515 (1998).
29. Willey, R.L., Klimkait, T., Frucht, D.M., Bonifacino, J.S. & Martin, M.A. Mutations within the human immunodeficiency virus type 1 gp160 envelope glycoprotein alter its itracellular transport and processing. Virology 184, 319-329 (1991).
30. Conley, A.J. et al. The consequence of passive administration of an anti-human immunodeficiency virus type 1 neutralizing monoclonal antibody before challenge of chimpanzees with a primary virus isolate. J. Virol. 70, 6751-6758 (1996).
31. National Institutes of Health in Guide for the Care and Use of Laboratory Animals, revised ed. DHHS publication number NIH 85-23 (1985).